Bimekizumab in Psoriasis: 3-Year Outcomes

• by Kathryn Wighton

• March 12, 2026

Integrated systems toxicology identifies TCDD-responsive targets linked to immune dysregulation and treatment response in psoriasis

• by Xuan Zhang, Yankun Zhang, Yanling He

• May 29, 2026

The role of protein lactylation in skin diseases: from molecular mechanisms to potential therapeutics

• by Yue Zhang, Zhinan Shi, Xiaohui Mo, Qiang Ju, Zhanyan Pan

• July 1, 2026

Does TYK2/JAK1 Show Potential in Inflammatory Diseases?

Investigational inhibitor was not associated with treatment-related serious adverse events and produced biomarker changes consistent with pathway inhibition in healthy volunteers.

• by Andrea Surnit

• July 6, 2026

• 3 min